Biomarker measurements are increasingly essential for drug development, whether for PK/PD assessments, toxicity analysis or first-in-human studies. They enable us to validate hypotheses and aid the difficult decisions that need to be taken when deciding which projects to develop and which to terminate. For drugs taken forward, judgments regarding dose, schedule and, more importantly, patient population, can be made more accurately.
Date: 16/01/2013 - 17/10/2013
Location: London, UK